Curative Biosciences, Inc.
CBDX
$0.00
$0.000.00%
OTC PK
| 03/31/2018 | 12/31/2017 | 09/30/2017 | 06/30/2017 | 03/31/2017 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 32.00K | 451.50K | 15.70K | 17.20K | 4.00K |
| Depreciation & Amortization | -- | -- | 700.00 | 700.00 | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.00K | 451.50K | 16.70K | 17.90K | 4.00K |
| Operating Income | -32.00K | -451.50K | -16.70K | -17.90K | -4.00K |
| Income Before Tax | -32.00K | -451.50K | -16.70K | -17.90K | -4.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -32.00K | -451.50K | -16.70K | -17.90K | -4.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -32.00K | -451.50K | -16.70K | -17.90K | -4.00K |
| EBIT | -32.00K | -451.50K | -16.70K | -17.90K | -4.00K |
| EBITDA | -31.50K | -450.80K | -16.00K | -17.20K | -3.30K |
| EPS Basic | 0.00 | -0.03 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | -0.02 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | -0.03 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | -0.02 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 19.57M | 16.09M | 15.71M | 15.74M | 15.71M |
| Average Diluted Shares Outstanding | 19.57M | 16.09M | 15.71M | 15.74M | 15.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |